October 23, 2026 · Science & Research Daily Digest
A digest of science, space, biomedicine, and climate research for October 23, 2026, with summaries, links, and commentary.
I. Space and Deep Space
1. NASA keeps Artemis III on a summer 2027 launch, with four astronauts on a roughly 14-day low-Earth-orbit docking flight (Spaceflight)
Summary:
Florida Today, in an update timestamped 2:10 p.m. ET on October 23, reported that NASA said that afternoon it remains on track to launch the four Artemis III astronauts in summer 2027 from Kennedy Space Center. The flight is a roughly 14-day mission in low Earth orbit to dock with and test lunar-lander articles from Blue Origin and SpaceX. The crewed landing is Artemis IV in 2028. The reported sequence is a Blue Moon test lander first, then the crew on SLS and Orion docking to it, then a Starship test lander, after which Orion undocks and docks with Starship. The mission uses SLS, New Glenn, and Starship. NASA’s Artemis page lists the 2027 crew as NASA astronauts Randy Bresnik, Frank Rubio, and Andre Douglas, with ESA astronaut Luca Parmitano. The 2 p.m. ET briefing at the Kennedy press site included Administrator Jared Isaacman, Associate Administrator Amit Kshatriya, and Artemis program manager Jeremy Parsons.
Links:
- Florida Today — NASA says it's on track to launch Artemis III astronauts in summer 2027
- NASA — Moon to Mars: Artemis
Commentary:
Summer 2027 and the roughly 14-day duration come from the newspaper’s Friday update; this confirms the low-Earth-orbit docking demonstration, with the south-pole landing still assigned to Artemis IV.
2. Safety advisers ask NASA to revisit Artemis IV, citing a latest estimate of about 22 launches to fuel the lander (Spaceflight)
Summary:
SpacePolicyOnline reported that at the October 22 quarterly meeting of NASA’s Aerospace Safety Advisory Panel, former astronaut Charlie Precourt said the panel had been told about 22 launches would be needed to supply the propellant for a lander to reach lunar orbit. Ars Technica quoted him putting the latest estimate at around 22 flights and noted that he did not name the vehicle. Ars adds that Blue Origin’s initial Blue Moon design does not use orbital refueling, and reads the figure as applying to Starship. SpaceX chief executive Elon Musk replied on X that the number was too high and would be more like 6 to 8. The panel also said in-space cryogenic transfer has not been demonstrated and orbiting cryogenic depots do not yet exist, and that NASA is requiring one uncrewed landing demonstration plus an engine restart, while not requiring a demonstration of liftoff back to lunar orbit. Precourt said the panel will formally recommend that NASA re-examine the objectives, and possibly the architecture, of Artemis IV and later missions. Those remarks were the immediate backdrop to the October 23 briefing at Kennedy.
Links:
- SpacePolicyOnline — NASA Safety Panel Concerned About Artemis IV, Future Access to LEO
- Ars Technica — Latest estimate for Starship launches required to support a Moon landing? 22
Commentary:
Twenty-two is the latest estimate the advisers said they had been given, and 6 to 8 is Musk’s reply; neither figure is a count of refueling flights already flown.
II. Biomedicine
3. Personalized mRNA vaccine intismeran plus pembrolizumab cut melanoma recurrence or death by 42% (Oncology)
Summary:
Nature reported on October 23 that Merck and Moderna’s Phase 3 results show the personalized mRNA vaccine intismeran, given with pembrolizumab, reduced the risk of skin cancer returning or the recipient dying by 42% compared with pembrolizumab plus placebo. The trial enrolled 1,137 people with moderate to advanced melanoma, after surgery, at 157 centers. The vaccine is built from neoantigens found by sequencing each participant’s tumor and is meant to reduce recurrence. Trial leader Georgina Long of the Melanoma Institute Australia said follow-up is about 25 months so far, with no major harmful side effects, and that overall survival will be watched for several more years. The key data were due at the European Society for Medical Oncology meeting in Madrid on October 24; after a leak on October 22, the companies released the main results. Nature reported that Moderna’s share price fell by around 25% after the leak.
Links:
Commentary:
The 42% figure is the reduction in recurrence or death at about 25 months; overall survival is still being followed, and the full presentation is set for October 24.
4. Bispecific T-cell agonist invika left disease unprogressed in 16 of 27 people at the optimal dose (Immunotherapy)
Summary:
The National Institutes of Health announced on October 23, pointing to the same day’s Nature Medicine paper on the Phase 1/2 START-001 trial, that invikafusp alfa (invika) is designed to activate two groups of tumor-infiltrating lymphocytes. Investigators at NIH’s National Cancer Institute, Mass General Brigham, and Memorial Sloan Kettering enrolled people with a range of solid tumors, most of which had responded poorly to immune checkpoint blockade. Of 27 participants treated at the optimal dose across both phases, disease did not progress in 16 (59.3%). Four (14.8%) had a greater than 30% decrease in targeted tumors, including two with metastatic colorectal cancer on seventh-line therapy and one with stage 4 non-small cell lung cancer after multiple prior treatments. Flu-like side effects were generally manageable with medication and supportive care. Sponsor Marengo Therapeutics has FDA Fast Track designation for antigen-rich metastatic colorectal cancer, and more recently the same designation for similar solid tumors regardless of tissue type after prior therapy that includes checkpoint inhibitors.
Links:
- NIH — A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
- Nature Medicine — START-001 trial of invikafusp alfa
Commentary:
The 59.3% is the share of 27 people at the optimal dose whose disease did not progress; tumor shrinkage above 30% was seen in four of them.
5. An off-the-shelf KRAS vaccine raised T-cell responses in 89 of 90 people with pancreatic cancer, and missed its disease-free survival endpoint (Oncology)
Summary:
Nature Medicine on October 23 published an open-access paper led by Ben George of Mayo Clinic, and Mayo issued a news release the same day. The Phase 2 AMPLIFY-7P trial (NCT05726864) randomized 2:1 patients with stage I–III KRAS-mutated pancreatic ductal adenocarcinoma who had no radiographic recurrence within six months of standard therapy: 96 received the off-the-shelf vaccine camupepimut (ELI-002 7P) and 48 were observed. The vaccine targets seven common KRAS mutations. Mayo notes that such mutations occur in about 90% of pancreatic ductal adenocarcinomas. The primary disease-free survival endpoint was not met: median 23.8 versus 21.2 months, hazard ratio 0.85, P = 0.5329. Of 90 vaccinated patients who could be evaluated, 89 (98.9%) developed T-cell responses against mutated KRAS. Responses more than 9.17-fold above baseline, seen in 74 of 90 (82.2%), were associated with better disease-free survival, hazard ratio 0.22, with median disease-free survival not reached versus 6.08 months. Grade 3 or higher adverse events were 10 of 96 (10.4%) versus 7 of 48 (14.6%) on observation. The authors say these signals will shape a confirmatory Phase 3.
Links:
- Nature Medicine — AMPLIFY-7P trial of a lymph-node-targeted mKRAS vaccine
- Mayo Clinic — Investigational vaccine generates immune response to KRAS mutations
Commentary:
The 98.9% figure is an immune-response rate among evaluable vaccine recipients; the disease-free survival difference in the full study population was not statistically significant.
6. The first participant was vaccinated in Bunia in a Bundibugyo virus trial, with 9,552 confirmed cases as of October 21 (Vaccines)
Summary:
The Institute of Tropical Medicine in Antwerp said on October 23 that the first participant was vaccinated that day in Bunia, Democratic Republic of the Congo, in Tumaini, an adaptive Phase 2/3 platform trial. The Ministry of Health leads the outbreak response. The Institut National de Recherche Biomédicale and the University of Antwerp co-lead and co-sponsor the study, which uses ring vaccination of high-risk contacts and is registered as NCT07842107. No vaccine is approved against Bundibugyo virus. The first candidate to enter is Ervebo, licensed against Ebola virus. Two CEPI-funded Bundibugyo-specific candidates, from Moderna and from the University of Oxford with the Serum Institute of India, are being prepared to enter next. The outbreak was declared on May 15, 2026. WHO determined it to be a Public Health Emergency of International Concern, and Africa CDC determined it to be a Public Health Emergency of Continental Security. As of October 21, 9,552 cases and 4,602 deaths had been confirmed in the DRC. The release calls this the largest recorded Bundibugyo outbreak and the second-largest Ebola outbreak to date. In a CEPI–Gavi arrangement, Gavi has committed up to US$40 million for manufacturing readiness once a vaccine is approved.
Links:
Commentary:
Today’s milestone is the first vaccination; efficacy results are not yet in, and Ervebo’s existing license is for Ebola virus.
III. Climate and Environment
7. Under a high-emissions scenario, extreme southward swings of the South Indian convergence zone go from one every 22 years to one every 10, with rainfall about 20% more intense (Climate)
Summary:
Nature Climate Change published a research briefing on October 23 of a paper published on October 20 by Haodong Wang, Tao Geng, Wenju Cai, and Xiaopei Lin, with affiliations including Ocean University of China and Laoshan Laboratory. Extreme southward swings of the South Indian convergence zone can bring floods to parts of southern Africa. The abstract reports that, under a high-emissions scenario, the frequency doubles from one event per 22 years in the twentieth century to one per 10 years in the twenty-first century, with an average 20% increase in rainfall intensity. Two mechanisms are described: the African continent warms faster than the Indian Ocean and strengthens northerly winds, and a poleward shift of the Southern Ocean westerlies speeds warming in the southern subtropical Indian Ocean and increases moisture transport from the Atlantic toward Africa. Extended data say the frequency increase does not depend on model selection or on a single emissions pathway. The change from 22 years to 10 years is the high-emissions figure. The authors suggest that more frequent southward migration may indicate higher flood risk in parts of southern Africa.
Links:
- Nature Climate Change — Climate warming boosts southern Africa’s rainfall extremes
- Nature Climate Change — Increased southward swings of the South Indian convergence zone
Commentary:
The doubling of frequency and the 20% rise in rainfall intensity are the high-emissions model result; the paper also reports a frequency increase under lower-emissions pathways.
8. NASA Langley and Virginia Energy signed a Space Act Agreement to feed POWER data into state energy planning (Energy)
Summary:
NASA’s Langley Research Center announced on October 23 a Space Act Agreement with the Virginia Department of Energy, signed at a ceremony in Hampton by Langley Deputy Director Allen Kilgore and Virginia Energy Director Vince Maiden. NASA will provide solar, meteorological, and future weather-risk datasets for the state’s energy-system modeling, including resiliency studies, resource analysis, and long-term planning for how extreme weather affects electricity demand, generation, and system stress. The data come from NASA’s Prediction of Worldwide Energy Resources (POWER), through a digital connection to Langley’s POWER platform, drawing on products from Langley, Goddard, and Ames. A map released with the announcement uses cooling degree days, the extent to which daily average temperatures exceed 50°F (10°C), averaged from 2001 to 2020, to show where cooling demand is highest in Virginia.
Links:
Commentary:
The agreement supplies datasets the state can put into its models; the release does not announce a new power plant or a dollar figure for investment.
9. The IPCC suspended its 65th plenary with the AR7 timeline still unset for a sixth time, and least developed countries warn it may miss the 2028 Global Stocktake (Climate policy)
Summary:
Down To Earth reported on October 23 that the publication dates for the three Working Group reports of the IPCC’s Seventh Assessment cycle remain unresolved. The 65th plenary met in Addis Ababa from October 12 to 16. Chair Jim Skea suspended the session on the evening of October 16 after the meeting ran long and many small delegations, including those from the most vulnerable countries, had to leave. In a statement on October 17 he said the suspension was to protect inclusive participation and that he would reconvene as soon as possible. It is the sixth time since 2024 that delegates have failed to agree a publication schedule, and the budget was also left open. On October 21 the Least Developed Countries group under the UNFCCC said it was disappointed, warning that the best available science could miss the second Global Stocktake under the Paris Agreement in 2028. Citing the Earth Negotiations Bulletin, the report says Saudi Arabia, India, Russia, Iran, Iraq, Algeria, Syria, and Belarus favored publishing the Working Group II and III reports in 2029, arguing that a shorter deadline could weaken rigor and participation.
Links:
Commentary:
The suspension keeps small delegations in the process; AR7 still has no publication schedule aligned with the 2028 Global Stocktake.
IV. Basic Research
10. Manchester and Lancaster isolated the uranium sandwich cation uranocenium, with a 5f1 ground state for uranium(V) (Chemistry)
Summary:
Nature Communications on October 23 published an open-access paper from the University of Manchester and Lancaster University, with Conrad A. P. Goodwin as corresponding author. Uranocene, the actinide analogue of ferrocene, was first made in 1968. Ferrocene is readily oxidized to a cation, and the higher oxidation states of uranocene had not been isolated. The team reports the uranocenium cation [U(V)(η8-C8H8)2]+. Electron paramagnetic resonance and magnetometry show that this formal uranium(V) complex has a 5f1 ground state. Greater uranium 5f and 6d mixing into filled delta-symmetry bonding orbitals, relative to uranocene, increases interorbital repulsion and counteracts the bond-length contraction expected on oxidation, so the uranium–carbon distances barely change in the solid state and the solution redox couple is close to ideally reversible. Manchester’s release says earlier attempts failed because the cation reacts with a commonly used electrolyte, and that it is stable under the conditions they used.
Links:
- Nature Communications — Isolation of uranocenium, the bis-[8]annulene uranium cation
- University of Manchester — Elusive uranium sandwich cation isolated
Commentary:
Stability is reported under the electrolyte conditions the team selected; the structural point is that covalency offsets the bond contraction expected on oxidation.
11. A room-temperature-stable zirconium(III) aryloxide is operated as a molecular qudit, with T1 up to 87 milliseconds (Quantum chemistry)
Summary:
Nature Chemistry on October 23 published an open-access paper by Maggie E. Mahaney, Yuxiang Zhu, Daniel N. Huh, and colleagues. Zirconium(III) tends to dimerize or disproportionate, and room-temperature-stable mononuclear complexes are rare. The authors isolated tris(aryloxide) zirconium(III) complexes. Density functional theory finds that the trigonal planar d1 geometry stabilizes a 4dz2–5s hybrid singly occupied orbital with little ligand contribution and about 25–27% s character, giving isotropic hyperfine coupling constants of 803–809 MHz. Isotope-selective pulsed electron paramagnetic resonance measured spin–lattice relaxation times T1 up to 87 milliseconds and dephasing times up to 123 microseconds, and the team coherently manipulated electronic and electronuclear transitions. The paper says coherent spin control in frozen solution was shown above liquid-nitrogen temperature, up to 120 K. Zirconium-91, about 11.2% natural abundance, has nuclear spin 5/2, and the authors present the complexes as molecular qudits based on a more earth-abundant metal.
Links:
Commentary:
The 87 milliseconds and 123 microseconds are relaxation and dephasing times in frozen solution, and coherent control was shown up to 120 K.
12. A chemistry-infused bandit searched a 12-dimensional space for hydrogen-evolution catalysts and found earth-abundant formulations at least comparable to platinum (Catalysis)
Summary:
Nature Communications on October 23 published an open-access paper from the University of California, Los Angeles, National Taiwan University, and the University of North Carolina at Chapel Hill, with authors including Yi-An Lai, Hao Ming Chen, and Chong Liu. The work connects an interpretable decision-making model to a fully automated electrochemical platform and searches a 12-dimensional space of synthetic conditions for the electrocatalytic hydrogen evolution reaction. Guided by a human chemistry hypothesis, the bandit uses a local quadratic approximation between conditions and activity near the region already explored. The paper reports previously unreported earth-abundant electrocatalysts at least comparable to platinum-based ones, and model-derived hypotheses for how synthetic conditions affect performance near those local optima. Chong Liu discloses support from the U.S. National Science Foundation under CHE-2247426. Experiments used a synchrotron in Taiwan and SPring-8 in Japan.
Links:
Commentary:
“At least comparable to platinum” is catalytic activity in this hydrogen-evolution search; the paper does not report electrolyzer lifetime or the cost of hydrogen.
Today's Summary
- Space: NASA kept Artemis III on a summer 2027 launch and a roughly 14-day low-Earth-orbit docking flight. Safety advisers, ahead of that briefing, cited a latest estimate of about 22 launches to fuel a lander and asked NASA to revisit the 2028 Artemis IV landing.
- Biomedicine: Intismeran plus pembrolizumab reduced melanoma recurrence or death by 42%. Invika left disease unprogressed in 16 of 27 people at the optimal dose. A pancreatic KRAS vaccine raised immune responses in 89 of 90 evaluable recipients and missed its disease-free survival endpoint. The Bundibugyo vaccine trial vaccinated its first participant in Bunia.
- Climate and environment: Under a high-emissions scenario, extreme southward swings of the South Indian convergence zone go from once every 22 years to once every 10, with rainfall intensity up 20% on average. NASA is supplying POWER energy data to Virginia. The IPCC’s 65th plenary adjourned with the AR7 schedule still unset.
- Basic research: Uranocenium was isolated, with a 5f1 ground state for uranium(V). A zirconium(III) aryloxide reached a T1 of up to 87 milliseconds. An interpretable autonomous campaign found earth-abundant hydrogen-evolution catalysts at least comparable to platinum.
Daily Framing:
October 23 was a readout-versus-schedule day: a melanoma Phase 3 cut recurrence or death by 42% while a pancreatic vaccine missed its disease-free survival endpoint, and NASA kept Artemis III on a summer 2027 low-Earth-orbit docking while safety advisers asked for a fresh look at the 2028 south-pole landing.
This digest is compiled from real-time search results and is for reference only.